In the wake of the COVID-19 pandemic, recent years’ data is not a reliable predictor of future mortality. Using the CDC’s death data and USCB’s population estimates, RGA has conducted a thorough analysis of emerging data to identify how US mortality has changed through the pandemic, determine what it looks like in the short term, and understand where it may be headed in the coming years.
RGA's full US mortality report is due out later this year – ask us about a sneak preview.
Analyzing historic mortality to support assumption setting for future mortality is a challenging task – one made more difficult in the wake of the acute phase, starting in March 2020 and ending in March 2022 – of the COVID-19 pandemic. Data from the last few years is clearly not a reliable predictor of future mortality, and actuaries can no longer steer assumptions by just looking in the rearview mirror. Figure 1 reflects the challenges of using recent mortality data.
Figure 1: What does the future hold?
Actual AADRs (red dotted line) and expected AADRs (gray line) for the US population from 2015 to January 2024 for all ages. The gray-shaded period from March 2020 onward is the COVID-19 period.
* Expected mortality rates come from an RGA-developed expected basis that uses US population mortality data from 2011-2019 inclusive. Improvement trends and seasonality are allowed for in the basis. The basis includes projected mortality rates for the 2020-2024 period which incorporate, and project improvement trends seen in the data. This basis is referred to as the “pre-pandemic expectation.”
** The standard population data used is the “2000 US Standard Population (Census P25-1130),” available here: https://seer.cancer.gov/stdpopulations/stdpop.singleages.html
Deviations between actual and expected death rates – i.e., excess mortality data – were massive during COVID-19’s acute phase. Since exiting that phase, excess mortality has lessened, and as COVID-19 is now endemic, the population has a greater level of inherent immunity against severe outcomes.
Nevertheless, it is also clear that 2023 mortality remained elevated relative to the pre-pandemic mortality expectation when allowing for improvements and seasonality. The challenge now is to understand how, given COVID-19’s impact, mortality will transition in the short-to-medium term to its long-term level, and what this long-term level might be.
Life insurers, public health officials, and actuaries across various domains are proposing frameworks, principles, and even estimates of future mortality. Their goal: to bridge the gap between how future mortality assumptions were set historically and how they could (or should) be set now that the acute phase has subsided. (See “UK Mortality Projections: Practical implications of CMI proposals” as an example.1) A review of the many proposals and counterproposals reveals uncertainty around future mortality trends over the short-to-medium term as the new mortality regimes settle in.
RGA has conducted a thorough analysis of emerging US population mortality data to identify how US mortality has changed through the pandemic, determine what it looks like in 2023 and early 2024, and to understand where it may be headed in the coming years.
This article, which is an introduction to a larger report to be published in 2024, explores the following:
US population mortality datasets are sizable and updated regularly. They contain granular details such as date of death, age at death, and cause of death information, and are readily and freely available. As the US records around 3 million deaths per annum, the data offers an advanced and credible perspective on short-term mortality.
During the height of the COVID-19 pandemic, monitoring excess mortality in real-time provided a comprehensive view of the pandemic’s impact beyond confirmed COVID-19 deaths and a better understanding of the crisis’ true toll. The excess death data included deaths indirectly caused by pandemic-related factors, such as disruptions to healthcare systems and economic hardships, and the longer-term effects of COVID-19 infection.
In the current post-pandemic era, the observed short-term changes in excess mortality are offering insight into medium-term and possibly longer-term changes. These insights can be used as inputs to create frameworks, principles, and approaches to set future mortality assumptions. They can also be used to validate outputs from the given frameworks and estimates provided by actuarial associations. Such insights have always been critical for pricing protection business and annuities but have become more important than ever as the industry emerges from the COVID-19 pandemic.
Monitoring emerging mortality experience requires three essential components: up-to-date death data, exposed-to-risk (exposure) data, and some expectation of mortality against which observed mortality can be measured.
The US Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS) provides authoritative US death data. Finalized death data through year-end 2022 is currently available from the CDC NCHS Vital Statistics Online Data Portal.2 Provisional and incomplete death counts are available from CDC NCHS’s mortality data via CDC’s Wide-Ranging ONLine Data for Epidemiologic Research (WONDER),3 the CDC portal for public health data, through the end of the prior week. Data are based on death certificates for US residents; each death certificate contains a single underlying cause of death, up to 20 multiple causes of death, and a myriad of demographic data. Death counts from CDC WONDER can be obtained pre-stratified by several variables, including place of residence (total US, region, state, and county), age group (including single-year-of-age cohorts), gender, date of death, place of death, and cause of death.
Users must exercise care and judgment when using the latest mortality data from WONDER. (See “Considerations for death data” in this paper for more on this.)
Raw death counts provide minimal value without exposure data. Exposure data must correspond to death data or be adjusted accordingly. The US Census Bureau (USCB),4 the official arbiter of national population numbers, provides both population estimates and projections, which can be used to develop exposure estimates. Alternative population estimates are available from other sources, but those estimates require careful review to ensure they correspond to the death data and cover all age ranges.
It is important to note that the USCB revises population estimates periodically as new data becomes available and methods are refined. Because of this, both population and exposure estimates can change, and results may change accordingly. By fall of 2024, the USCB expects to release the 2010 to 2020 Intercensal Estimates – the official population estimates for the 2010-2020 decade .
Understanding how current mortality has changed compared to pre-pandemic expectations requires an expected mortality basis, i.e., some form of expected mortality, against which to measure. Expected mortality is critical to determining excess mortality and its likely trajectory. (Considerations for expected mortality are explored later in this article.)
Understanding changes in the drivers of mortality requires identifying underlying causes of death and breaking down expected mortality by cause. The cause definitions in the expected basis must align with the cause definitions in the death data to ensure they are comparable. This may sound obvious and straightforward, but anyone who has tried to reconcile causes of death across multiple International Classification of Disease (ICD) versions knows it is neither.
Just as there are incurred but not reported/recorded (IBNR) claims in the insurance world, there are IBNR deaths in the death data from WONDER. The reason for this is that the death data from WONDER are provisional: It can take several weeks for death records to be submitted to the NCHS, processed, coded, and then tabulated. Consequently, provisional data may be incomplete, especially for more recent time periods. Death counts for the latest weeks are revised regularly, and may increase or decrease, as data from new and updated death certificates are received. Importantly, for recent periods, death counts in WONDER data are incomplete and not the counts that will ultimately be observed; the CDC does not gross up initial values for IBNR deaths to estimate where they might ultimately land, and such estimates are not readily available.
Actuaries (and other like-minded professionals) can develop reasonable gross-up factors through relentless data collection and tracking how initial death counts progress over long time frames. Importantly, this data monitoring and later data interrogation allows the application of sensible confidence intervals to recent estimates. Estimating IBNR requires a deep understanding of how death data are reported.
Quality and robust expected mortality rates are critical for useful analyses. They will determine excess deaths where:
The expected deaths are what, before the pandemic’s onset, would have been anticipated for the current period, but still allowing for improvements (and seasonality if needed).
For interested readers, this section sets out considerations for setting expected mortality rates.
A typical approach to setting expected mortality rates is to set base mortality rates, then overlay estimated and projected improvements, and then overlay seasonality adjustments if the analyses are at a monthly or weekly level. This approach is useful for setting expected rates for both all-cause mortality and specific causes of death. It is necessary to consider how to group different causes in the data when setting expected rates by cause; less significant causes of death have mortality rates too volatile to work within this type of analysis.
Mortality improvements must also be included to allow for a realistic view of any excess mortality that needs to be understood and explained. This more complete view informs the insights drawn from even short-term mortality changes and trajectories.
Figure 2: Improvements in all-cause mortality for males and females at ages 35 and 85 for 2011-2023
Estimates from the Society of Actuaries’ Mortality Improvement Model could be used for all-cause mortality.5 But wherever or however derived, it is important to ensure that improvements are aligned with base mortality rates and the data used.
Mortality improvements will also vary by cause. Setting by-cause improvement assumptions will require judgement and pragmatism where the death data is sparse.
Death data from CDC WONDER is available at annual, monthly, and weekly resolutions. The analyses carried out by RGA use a monthly resolution. This requires including seasonality adjustments in the expected basis, as significant seasonality is frequently observed at monthly levels in the US.
Seasonality varies by age and is most pronounced for older lives for all-cause mortality, as illustrated in Figure 3 for all-cause mortality. That said, seasonality can be observed for younger lives when mortality is broken down by cause. For example, Figure 4 shows crude mortality rates for “other accidents” (non-transport accidents) and reveals elevated mortality for younger lives in the summer months.
The analyses that underlie the forthcoming full report use a pre-pandemic expected basis developed from the data described above. The expected bases are for all-cause and by-cause, and in all cases make allowances for improvement trends and seasonality. The improvements capture the trends observed in data and mortality rates are projected out for 2020 to 2024 with these trends.
Extracting insights for insured lives is a significant challenge when considering population-level mortality results. In many countries, for varied reasons, but notably underwriting, insured lives can have significantly different mortality levels from those of the general population. The differences in mortality among insured lives may also vary depending on the product and the provider.
To translate population-level mortality insights into insured life insights requires a thorough understanding of a carrier’s book of business. Even then, appreciable uncertainty may remain and mandate the use of judgment.
US population mortality data is a valuable data source. Challenges translating population-level insights to insured insights and to other countries are unavoidable given the US’s unique characteristics, such as its obesity epidemic, widespread opioid abuse, and lack of universal healthcare. That said, with the right data and approach, US population mortality can be a key source of granular and current mortality experience, and the emerging US results may provide leading insights into mortality trends in insured lives applicable to multiple markets.
RGA’s full US mortality report is due out later this year – ask us about a sneak preview.
